AbbVie Inc (ABBV)

How it makes money

AbbVie generates revenue primarily through the sale of branded pharmaceutical products. Revenue is driven by physician prescriptions for patients in developed and emerging markets, supported by direct sales forces and partnerships with healthcare providers, managed care organizations, and government healthcare programs.

AbbVie possesses a durable competitive advantage through an extensive patent portfolio protecting key products. Skyrizi and Rinvoq, which collectively generated $17.6 billion in 2024 revenues, benefit from composition-of-matter patents with exclusive protection extending to 2033. The company's integrated R&D and manufacturing capabilities, established market positions across multiple therapeutic areas, and a pipeline of approximately 90 compounds create substantial barriers to entry. Brand loyalty among physicians and healthcare systems, combined with regulatory approval barriers for competitor products, reinforce the moat.

AbbVie's demand is moderately cyclical. Immunology demand reflects underlying disease prevalence (rheumatoid arthritis, psoriasis, inflammatory bowel disease) which remains relatively stable but is influenced by aging populations, rising obesity, and diagnostic improvement. Oncology demand is driven by cancer incidence which increases with age and is generally resilient to economic cycles. However, healthcare spending and access are influenced by insurance coverage decisions, government healthcare budgets, and economic conditions affecting patient compliance.

Key risks

• Patent Expiration and Biosimilar Competition — AbbVie faces material revenue risk from patent expiration and biosimilar entry. Humira, a former flagship product, experienced a 40.8% revenue decline in 2024 following biosimilar competition after loss of exclusivity in January 2023. The immunology portfolio, which generated $26.7 billion in 2024, depends heavily on Skyrizi and Rinvoq; their composition-of-matter patents expire in 2033, after which biosimilar competitors may enter the market.
• Regulatory Approval and Clinical Development Risk — AbbVie's future growth depends on regulatory approval of pipeline candidates. Approximately 90 compounds and indications are in development; clinical failures, regulatory delays, or unexpected adverse safety findings could materially impair revenue growth. The company carries indefinite-lived intangible assets related to unapproved IPR&D programs that require annual impairment assessment.
• Pricing and Reimbursement Pressures — AbbVie faces significant pricing pressures from government healthcare programs and private payers globally. Cost-containment efforts, rebates, chargebacks, and price controls by authorities in developed markets could reduce revenues and operating margins. In the United States, managed care providers, Medicare, Medicaid, and the Department of Veterans Affairs are substantial customers whose negotiating power affects pricing.
• R&D Execution and Pipeline Risk — AbbVie invested $10.8 billion in R&D in 2024. Success depends on advancing the pipeline efficiently. Manufacturing challenges, supply disruptions, clinical trial setbacks, or competitive products reaching market could impair the company's ability to replace declining products and achieve growth targets.
• Intense Competition in Key Therapeutic Areas — Immunology and oncology markets are highly competitive with multiple companies developing similar mechanisms of action. Competitors may develop more efficacious therapies, obtain approvals more quickly, or establish stronger market positions, reducing AbbVie's market share and pricing power in these core therapeutic areas.
• Product Liability and Litigation — AbbVie faces potential product liability claims and patent-related litigation. While management does not believe such matters will materially affect financial condition, substantial litigation expenses or unfavorable verdicts could impact results. The company also faces legacy product liability exposure.

AbbVie has no single customer that, if lost, would have a material adverse effect on the business. However, the company has substantial customer concentration through wholesale distributors in the United States. Three wholesale distributors (McKesson Corporation, Cardinal Health, Inc., and Cencora, Inc.) account for substantially all U.S. pharmaceutical product sales, and these three wholesalers collectively represent 81% of accounts receivable. No individual wholesaler accounted for more than 39% of 2024 gross revenues. Significant customers also include managed care organizations, hospitals, and government agencies including Medicare, Medicaid, and the Department of Veterans Affairs.